A recent study has demonstrated how RNA sequencing can enhance the genetic classification of B-cell precursor acute ...
When exposed to antibiotics, approximately one out of every 10 8 -10 9 bacteria develops resistance due to spontaneous ...
Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...
MedPage Today on MSN1d
siRNA Agent Slashes Lipoprotein(a) LevelsNovel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared ...
Large-scale data on the hepatitis D virus (HDV)/hepatitis B virus (HBV) co-infection rate is needed to estimate the current ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Quantbot Technologies LP acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the ...
Researchers say they are exploring therapeutic options to block fatty acid accumulation and immunosuppressive signals between ...
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback